163 related articles for article (PubMed ID: 23078653)
21. Inhibition factors of arsenic trioxide therapeutic effects in patients with acute promyelocytic leukemia.
Sui M; Zhang Z; Zhou J
Chin Med J (Engl); 2014; 127(19):3503-6. PubMed ID: 25269921
[TBL] [Abstract][Full Text] [Related]
22. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
23. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study.
Gill H; Yim R; Lee HKK; Mak V; Lin SY; Kho B; Yip SF; Lau JSM; Li W; Ip HW; Hwang YY; Chan TSY; Tse E; Au WY; Kumana CR; Kwong YL
Cancer; 2018 Jun; 124(11):2316-2326. PubMed ID: 29579321
[TBL] [Abstract][Full Text] [Related]
25. A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide.
Kulkarni U; Ganesan S; Alex AA; Palani H; David S; Balasundaram N; Venkatraman A; Thenmozhi M; Jeyaseelan L; Korula A; Devasia A; Abraham A; Janet NB; Balasubramanian P; George B; Mathews V
Cancer Med; 2020 Apr; 9(8):2603-2610. PubMed ID: 32059085
[TBL] [Abstract][Full Text] [Related]
26. Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5-year prospective study.
Gill H; Kumana CR; Yim R; Hwang YY; Chan TSY; Yip SF; Lee HKK; Mak V; Lau JSM; Chan CC; Kho B; Wong RSM; Li W; Lin SY; Lau CK; Ip HW; Leung RYY; Lam CCK; Kwong YL
Cancer; 2019 Sep; 125(17):3001-3012. PubMed ID: 31090936
[TBL] [Abstract][Full Text] [Related]
27. Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report.
Boddu P; Schlette E; Thakral B; Tang G; Pemmaraju N; Kadia T; Ferrajoli A; Ravandi F; Wierda W; Jain N
Hematol Oncol Stem Cell Ther; 2019 Sep; 12(3):161-165. PubMed ID: 28830803
[TBL] [Abstract][Full Text] [Related]
28. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
Soignet SL; Maslak P; Wang ZG; Jhanwar S; Calleja E; Dardashti LJ; Corso D; DeBlasio A; Gabrilove J; Scheinberg DA; Pandolfi PP; Warrell RP
N Engl J Med; 1998 Nov; 339(19):1341-8. PubMed ID: 9801394
[TBL] [Abstract][Full Text] [Related]
29. Relapsed/refractory acute promyelocytic leukemia with RARA-LBD region mutation was salvaged by venetoclax: A case report.
Li Y; Yu J; Xu Q; Zhang K
Medicine (Baltimore); 2021 Dec; 100(48):e28076. PubMed ID: 35049232
[TBL] [Abstract][Full Text] [Related]
30. [Effects of combination therapy with all-trans retinoic acid and arsenic trioxide on acute promyelocytic leukemia].
Zhang GC; Zheng D; Li QH; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Apr; 23(4):430-4. PubMed ID: 15087033
[TBL] [Abstract][Full Text] [Related]
31. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia.
Soignet SL
Oncologist; 2001; 6 Suppl 2():11-6. PubMed ID: 11331435
[TBL] [Abstract][Full Text] [Related]
32. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
33. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
[TBL] [Abstract][Full Text] [Related]
34. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
[TBL] [Abstract][Full Text] [Related]
35. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
[TBL] [Abstract][Full Text] [Related]
36. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.
Shen ZX; Chen GQ; Ni JH; Li XS; Xiong SM; Qiu QY; Zhu J; Tang W; Sun GL; Yang KQ; Chen Y; Zhou L; Fang ZW; Wang YT; Ma J; Zhang P; Zhang TD; Chen SJ; Chen Z; Wang ZY
Blood; 1997 May; 89(9):3354-60. PubMed ID: 9129042
[TBL] [Abstract][Full Text] [Related]
37. [Molecular remission induced by gemtuzumab ozogamicin in an elderly patient with relapsed acute promyelocytic leukemia].
Yago K; Aono M; Shimada H
Rinsho Ketsueki; 2010 Apr; 51(4):286-90. PubMed ID: 20467227
[TBL] [Abstract][Full Text] [Related]
38. Oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long-term results and unique prognostic indicators.
Gill HS; Yim R; Kumana CR; Tse E; Kwong YL
Cancer; 2020 Jul; 126(14):3244-3254. PubMed ID: 32365228
[TBL] [Abstract][Full Text] [Related]
39. Arsenic trioxide for acute promyelocytic leukemia in a patient on chronic hemodialysis.
Tinajero J; El-Shami K; Wu X; Smith BD; Newman MJ
Leuk Res Rep; 2022; 17():100304. PubMed ID: 35371914
[TBL] [Abstract][Full Text] [Related]
40. A review of arsenic trioxide and acute promyelocytic leukemia.
Alimoghaddam K
Int J Hematol Oncol Stem Cell Res; 2014 Jul; 8(3):44-54. PubMed ID: 25642308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]